Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
P/B ratio for Amarin Corporation plc (AMRN)
P/B ratio as of 2023: 0.64
According to Amarin Corporation plc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.64. At the end of 2022 the company had a P/B ratio of 0.82.
P/B ratio history for Amarin Corporation plc from 1993 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.64 |
| 2022 | 0.82 |
| 2021 | 2.00 |
| 2020 | 2.97 |
| 2019 | 12.07 |
| 2018 | 26.56 |
| 2017 | -16.67 |
| 2016 | -71.61 |
| 2015 | -2.63 |
| 2014 | -1.92 |
| 2013 | -9.37 |
| 2012 | -291.49 |
| 2011 | -163.63 |
| 2010 | -4.06 |
| 2009 | 1.25 |
| 2008 | 0.54 |
| 2007 | 1.01 |
| 2006 | 4.84 |
| 2005 | 1.26 |
| 2004 | 2.91 |
| 2003 | -4.15 |
| 2002 | -6.00 |
| 2001 | 41.72 |
| 2000 | 0.26 |
| 1999 | 5.85 |
| 1998 | -3.11 |
| 1997 | 4.78 |
| 1996 | 4.79 |
| 1995 | 4.06 |
| 1994 | 0.00 |
| 1993 | 8.38 |